Piperaquine tetraphosphate
Eurartesim (piperaquine tetraphosphate) is a small molecule pharmaceutical. Piperaquine tetraphosphate was first approved as Eurartesim on 2011-10-27. It has been approved in Europe to treat malaria.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
HCPCS
No data
Clinical
Clinical Trials
171 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Malaria | D008288 | EFO_0001068 | B54 | 17 | 23 | 55 | 45 | 27 | 156 |
| Falciparum malaria | D016778 | EFO_0007444 | B50 | 7 | 14 | 18 | 16 | 15 | 64 |
| Vivax malaria | D016780 | EFO_0007445 | B51 | 2 | 3 | 5 | 3 | 4 | 16 |
| Anemia | D000740 | EFO_0004272 | D64.9 | — | — | 4 | 4 | — | 8 |
| Healthy volunteers/patients | — | — | — | 5 | — | 1 | 2 | — | 8 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | 2 | 2 | — | 4 |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | — | 3 | 1 | — | 4 |
| Pharmacokinetics | D010599 | — | — | 1 | — | — | 1 | — | 2 |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | — | — | 1 | 1 | — | 2 |
| Parasitic diseases | D010272 | EFO_0001067 | B88 | — | — | — | 1 | — | 1 |
Show 4 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pregnancy rate | D018873 | — | — | — | — | 2 | — | — | 2 |
| Disease susceptibility | D004198 | — | — | — | — | 1 | — | — | 1 |
| Fever | D005334 | — | R50.9 | — | — | 1 | — | — | 1 |
| Therapeutics | D013812 | — | — | — | — | 1 | — | — | 1 |
| Asymptomatic diseases | D058070 | — | — | — | — | 1 | — | — | 1 |
| Bacterial vaginosis | D016585 | EFO_0003932 | — | — | — | 1 | — | — | 1 |
| Vaginitis | D014627 | EFO_0005757 | N76 | — | — | 1 | — | — | 1 |
| Vaginal diseases | D014623 | — | — | — | — | 1 | — | — | 1 |
| Trichomonas vaginitis | D014247 | EFO_0007521 | — | — | — | 1 | — | — | 1 |
| Trichomonas infections | D014245 | DOID_1947 | A59 | — | — | 1 | — | — | 1 |
Show 10 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infections | D007239 | EFO_0000544 | — | 1 | 1 | — | — | 2 | 4 |
| Cardiotoxicity | D066126 | EFO_1001482 | — | — | 1 | — | — | — | 1 |
| Parasitemia | D018512 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Communicable diseases | D003141 | — | — | 1 | — | — | — | 2 | 3 |
| Combination drug therapy | D004359 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Drug resistance | D004351 | — | Z16.30 | — | — | — | — | 1 | 1 |
| Neurobehavioral manifestations | D019954 | EFO_0004364 | — | — | — | — | — | 1 | 1 |
| Chemoprevention | D018890 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Piperaquine tetraphosphate |
| INN | — |
| Description | Piperaquine is an aminoquinoline that is 1,3-di(piperazin-1-yl)propane in which the nitrogen at position 4 of each of the piperazine moieties is replaced by a 7-chloroquinolin-4-yl group. It has a role as an antimalarial. It is a N-arylpiperazine, an organochlorine compound and an aminoquinoline. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Clc1ccc2c(N3CCN(CCCN4CCN(c5ccnc6cc(Cl)ccc56)CC4)CC3)ccnc2c1.O=P(O)(O)O.O=P(O)(O)O.O=P(O)(O)O.O=P(O)(O)O |
Identifiers
| PDB | — |
| CAS-ID | 4085-31-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1652442 |
| ChEBI ID | — |
| PubChem CID | 122262 |
| DrugBank | DB13941 |
| UNII ID | — |
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
40 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use